CoChat

Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis

Open access
Devoe, Daniel J, Peterson, Aaron, Addington, Jean · 2018 · Schizophrenia Bulletin
Cited by 80

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Objective: Youth at clinical high risk (CHR) for psychosis often demonstrate significant negative symptoms, which have been reported to be predictive of conversion to psychosis and a reduced quality of life but treatment options for negative symptoms remain inadequate. Therefore, we conducted a systematic review and network meta-analysis of all intervention studies examining negative symptom outcomes in youth at CHR for psychosis. Method: The authors searched PsycINFO, Medline, Embase, CINAHL, and EBM from inception to December 2016. Studies were selected if they included any intervention that reported follow-up negative symptoms in youth at CHR for psychosis. Treatment comparisons were evaluated using both pairwise and network meta-analyses. Due to the differences in negative symptom scales the effect sizes were reported as the standardized mean difference (SMD). Results: Of 3027 citations, 32 studies met our inclusion criteria, including a total of 2463 CHR participants. The null hypothesis was not rejected for any of the 11 treatments. N-methyl-D-aspartate-receptor (NMDAR) modulators trended toward a significant reduction in negative symptoms compared to placebo (SMD = -0.54; 95% CI = -1.09 to 0.02; I2 = 0%, P = .06). In respective order of descending effectiveness as per the treatment hierarchy, NMDAR modulators were more effective than family therapy, need-based interventions, risperidone, amisulpride, cognitive behavioral therapy, omega-3, olanzapine, supportive therapy, and integrated psychological interventions. Conclusions: Efficacy and effectiveness were not confirmed for any negative symptom treatment. Many studies had small samples and the majority were not designed to target negative symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/schbul/sbx139

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 67

  1. McGlashan, 2010, The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-up
  2. Yung, 2005, Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States, Aust N Z J Psychiatry, 39, 964, 10.1080/j.1440-1614.2005.01714.x · DOI · Paper page
  3. Fusar-Poli, 2007, Integrating the negative psychotic symptoms in the high risk criteria for the prediction of psychosis, Med Hypotheses, 69, 959, 10.1016/j.mehy.2006.12.044 · DOI
  4. Lencz, 2004, Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia, Schizophr Res, 68, 37, 10.1016/S0920-9964(03)00214-7 · DOI · Paper page
  5. Piskulic, 2012, Negative symptoms in individuals at clinical high risk of psychosis, Psychiatry Res, 196, 220, 10.1016/j.psychres.2012.02.018 · DOI · Paper page
  6. Mason, 2004, Risk factors for transition to first episode psychosis among individuals with ‘at-risk mental states’, Schizophr Res, 71, 227, 10.1016/j.schres.2004.04.006 · DOI · Paper page
  7. Demjaha, 2012, Disorganization/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis, Schizophr Bull, 38, 351, 10.1093/schbul/sbq088 · DOI · Paper page
  8. Devoe, 2017, SU127. Negative symptoms in youth at clinical high risk of psychosis, Schizophr Bull, 43, S207, 10.1093/schbul/sbx024.123 · doi:10.1093/schbul/sbx024.123
  9. Bechdolf, 2005, Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls, Schizophr Res, 79, 137, 10.1016/j.schres.2005.06.008 · DOI
  10. Nelson, 2013, Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: the PACE 400 study, JAMA Psychiatry, 70, 793, 10.1001/jamapsychiatry.2013.1270 · DOI · Paper page
  11. Domínguez-Martínez, 2015, Subjective quality of life in At-Risk Mental State for psychosis patients: relationship with symptom severity and functional impairment, Early Interv Psychiatry, 9, 292, 10.1111/eip.12111 · DOI
  12. Wood, 2014, Negative symptoms in the at-risk mental state—association with transition to psychosis and functional outcome, Early Interv Psychiatry, 8, 23
  13. Fusar-Poli, 2015, Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials, Schizophr Bull, 41, 892, 10.1093/schbul/sbu170 · DOI · Paper page
  14. Carpenter, 2015, Diagnostic concepts in the context of clinical high risk/attenuated psychosis syndrome, Schizophr Bull, 41, 1001, 10.1093/schbul/sbv095 · DOI
  15. Kantrowitz, 2010, N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia, Brain Res Bull, 83, 108, 10.1016/j.brainresbull.2010.04.006 · DOI · Paper page
  16. Kantrowitz, 2016, “D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial”: correction, Lancet Psychiatry, 3, 602
  17. Amminger, 2010, Indicated prevention with long-chain omega-3 fatty acids in young people at ultra-high risk for psychosis: a randomized, placebo-controlled trial, Early Interv Psychiatry, 4, 7
  18. Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, 339, b2700, 10.1136/bmj.b2700 · DOI · Paper page
  19. Stroup, 2000, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group, JAMA, 283, 2008, 10.1001/jama.283.15.2008 · DOI · Paper page
  20. Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ, 339:b2535
  21. Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, 13, 261, 10.1093/schbul/13.2.261 · DOI · Paper page
  22. Andreasen, 1989;17:173–180, Scale for the Assessment of Negative Symptoms (SANS), Br J Psychiatry Suppl, 10.1192/S0007125000291496 · DOI · Paper page
  23. Miller, 2003, Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability, Schizophr Bull, 29, 703, 10.1093/oxfordjournals.schbul.a007040 · DOI · Paper page
  24. Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions
  25. Boyle, 2013, Evaluation of the reliability and validity of GraphClick as a data extraction program, Comput Human Behav, 29, 1023, 10.1016/j.chb.2012.07.031 · DOI
  26. Peterson, 2011, The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses
  27. Woods, 2013, Glycine treatment of the risk syndrome for psychosis: report of two pilot studies, Eur Neuropsychopharmacol, 23, 931, 10.1016/j.euroneuro.2012.09.008 · DOI · Paper page
  28. DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  29. Collaboration, 2011, Review manager (RevMan) [computer program]: Version
  30. Becker, 2000, Effect Size (ES)
  31. Bucher, 1997, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials, J Clin Epidemiol, 50, 683, 10.1016/S0895-4356(97)00049-8 · DOI · Paper page
  32. Cates, 2014, Maintenance treatment for adults with chronic asthma, BMJ, 348:g3148
  33. Dias, 2013, Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials, Med Decis Making, 33, 641, 10.1177/0272989X12455847 · DOI · Paper page
  34. Song, 2003, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses, BMJ, 326, 472, 10.1136/bmj.326.7387.472 · DOI · Paper page
  35. Cohen, 1988, Statistical Power Analysis for the Behavioral Sciences, 20
  36. Woods, 2007, Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study, Br J Psychiatry Suppl, 51, s96, 10.1192/bjp.191.51.s96 · DOI
  37. Piskulic, 2012, Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis, Schizophr Res, 136, S245, 10.1016/S0920-9964(12)70739-9 · doi:10.1016/s0920-9964(12)70739-9
  38. McFarlane, 2015, Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial, Schizophr Bull, 41, 30, 10.1093/schbul/sbu108 · DOI · Paper page
  39. Loewy, 2016, Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis, Schizophr Bull, 42, S118, 10.1093/schbul/sbw009 · DOI · Paper page
  40. Landa, 2016, Development of a group and family-based cognitive behavioural therapy program for youth at risk for psychosis, Early Interv Psychiatry, 10, 511, 10.1111/eip.12204 · DOI
  41. Hooker, 2014, A pilot study of cognitive training in clinical high risk for psychosis: initial evidence of cognitive benefit, Schizophr Res, 157, 314, 10.1016/j.schres.2014.05.034 · DOI · Paper page
  42. Choi, 2017, Pupillometer-based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis, Psychiatr Rehabil J, 40, 33, 10.1037/prj0000217 · DOI · Paper page
  43. Cadenhead, 2017, 23. Omega-3 fatty acid versus placebo in a clinical high-risk sample from the North American Prodrome Longitudinal Studies (NAPLS) Consortium, Schizophr Bull, 43, S16, 10.1093/schbul/sbx021.042 · DOI
  44. Cannon, 2002, Antipsychotic drug treatment in the prodromal phase of schizophrenia, Am J Psychiatry, 159, 1230, 10.1176/appi.ajp.159.7.1230 · DOI
  45. Ising, 2016, Four-year follow-up of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE-NL) trial, Schizophr Bull, 42, 1243, 10.1093/schbul/sbw018 · DOI · Paper page
  46. Wessels, 2015, Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis, Psychiatr Prax, 42, 313
  47. Urben, 2012, A randomized controlled trial of the effectiveness of a computer-assisted cognitive remediation (CACR) program in adolescents with psychosis or at high risk of psychosis: short term and long term outcomes, Early Interv Psychiatry, 6, 41
  48. McGorry, 2013, Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome, J Clin Psychiatry, 74, 349, 10.4088/JCP.12m07785 · DOI · Paper page
  49. Berger, 2012, Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study, Curr Pharm Des, 18, 570, 10.2174/138161212799316163 · DOI · Paper page
  50. McGorry, 2017, Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial, JAMA Psychiatry, 74, 19, 10.1001/jamapsychiatry.2016.2902 · DOI · Paper page
  51. Kobayashi, 2009, Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state, J Clin Psychopharmacol, 29, 421, 10.1097/JCP.0b013e3181b2fe22 · DOI
  52. Liu, 2012, Aripiprazole for drug-naive or antipsychotic-short-exposure subjects at putatively prodromal or early state of psychosis: an open-label study, Early Interv Psychiatry, 6, 101
  53. Washida, 2013, Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia, Neuropsychiatr Dis Treat, 9, 861, 10.2147/NDT.S45697 · DOI
  54. Tsujino, 2013, Long-term efficacy and tolerability of perospirone for young help-seeking people at clinical high risk: a preliminary open trial, Clin Psychopharmacol Neurosci, 11, 132, 10.9758/cpn.2013.11.3.132 · DOI
  55. Kumar, 2014, Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: an open-label clinical study, Ind Psychiatry J, 23, 27, 10.4103/0972-6748.144953 · DOI
  56. Danion, 1999, Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride, Am J Psychiatry, 156, 610, 10.1176/ajp.156.4.610 · DOI · Paper page
  57. Kim, 1980, Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia, Neurosci Lett, 20, 379, 10.1016/0304-3940(80)90178-0 · DOI · Paper page
  58. Heresco-Levy, 1999, Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia, Arch Gen Psychiatry, 56, 29, 10.1001/archpsyc.56.1.29 · DOI · Paper page
  59. Miyake, 2016, Effects of N-acetylcysteine on cognitive functions in subjects with an at-risk mental state: a case series, J Clin Psychopharmacol, 36, 87, 10.1097/JCP.0000000000000445 · DOI
  60. Sommer, 2016, Early interventions in risk groups for schizophrenia: what are we waiting for, NPJ Schizophr, 2, 16003, 10.1038/npjschz.2016.3 · DOI · Paper page
  61. Marder, 2011, Methodological issues in negative symptom trials, Schizophr Bull, 37, 250, 10.1093/schbul/sbq161 · DOI · Paper page
  62. Kirkpatrick, 2006, The NIMH-MATRICS consensus statement on negative symptoms, Schizophr Bull, 32, 214, 10.1093/schbul/sbj053 · DOI · Paper page
  63. Pelletier-Baldelli, Initial development and preliminary psychometric properties of the Prodromal Inventory of Negative Symptoms (PINS), Schizophr Res
  64. Corcoran, 2011, The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis, Psychol Med, 41, 251, 10.1017/S0033291710000802 · DOI · Paper page
  65. Dong, 2015, Early intervention for psychosis with N-methyl-d-aspartate receptor modulators, Clin Psychopharmacol Neurosci, 13, 328, 10.9758/cpn.2015.13.3.328 · DOI
  66. Woods, 2014, NMDAR-based treatments for patients at clinical high risk for psychosis, Biol Psychiatry, 1, 11S
  67. Yung, 2012, Whither the attenuated psychosis syndrome, Schizophr Bull, 38, 1130, 10.1093/schbul/sbs108 · DOI · Paper page

Cited by

See all 80

Metadata

Authors
Devoe, D. J., Peterson, A., & Addington, J.
Venue
Schizophrenia Bulletin
Published
2017-10-24
Volume
44
Issue
4
Pages
807-823
ISSN
  • 0586-7614 (ISSN-L)
  • 1745-1701
OpenAlex
W2765822046
Cited by
80
References
32
FWCI
1.71
Type
journal article
Language
en
Open access
green
Funders
National Institute of Mental Health (RO1MH105178)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis. https://app.cochat.ai/papers/10.1093/schbul/sbx139
The paper
Devoe, D. J., Peterson, A., & Addington, J. (2018). Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbx139

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.